Kuehn Law Encourages FUSN, KAMN, DRQ, and VZIO Investors to Contact Law Firm
–News Direct–
Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process:
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) click to participate
Fusion Pharmaceuticals has agreed to be acquired by AstraZeneca. Under the agreement, shareholders of Fusion will be entitled to a payment of $21.00 per share in cash plus a non-transferable CVR of $3.00.
Kaman Corp. (NYSE: KAMN) click to participate
Kaman has reached a deal to be quire...